Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021040673 - METHODS FOR THE TREATMENT OF CHRONIC HYPOXEMIA AND INHIBITING LUNG FIBROSIS IN PATIENTS WITH PULMONARY FIBROSIS WITH AND WITHOUT COPD

Publication Number WO/2021/040673
Publication Date 04.03.2021
International Application No. PCT/US2019/000041
International Filing Date 26.08.2019
IPC
A61K 31/19 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
A61K 31/198 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/4174 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
CPC
A61K 31/194
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
194having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/4174
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 33/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
06Aluminium, calcium or magnesium; Compounds thereof ; , e.g. clay
10Carbonates; Bicarbonates
A61K 33/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
42Phosphorus; Compounds thereof
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • MARTIN, Alain [US]/[US]
Inventors
  • MARTIN, Alain
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR THE TREATMENT OF CHRONIC HYPOXEMIA AND INHIBITING LUNG FIBROSIS IN PATIENTS WITH PULMONARY FIBROSIS WITH AND WITHOUT COPD
(FR) MÉTHODES DE TRAITEMENT DE L'HYPOXÉMIE CHRONIQUE ET D'INHIBITION DE LA FIBROSE PULMONAIRE CHEZ DES PATIENTS ATTEINTS DE FIBROSE PULMONAIRE AVEC ET SANS BPCO
Abstract
(EN)
The present invention involves methods for the treatment of chronic hypoxemia, COPD and lung fibrosis in patients with both COPD and pulmonary fibrosis, and in patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, prevent hypoxemia while reducing the sinus and lung infections, reducing some drug side effects, inhibiting fibrosis and reducing coughing and nasal erythema. These methods include the following steps: A) analyzing and diagnosing a patient with a lung ailment elected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B.) treating the patient to raise the patient's lung functions including FEV1/ FVC ratio by contacting mammalian cells with a therapeutically effective amount of a treatment composition that includes a therapeutically effective amount of each constituent of the composition.
(FR)
La présente invention concerne des méthodes pour le traitement de l'hypoxémie chronique, la BPCO et la fibrose pulmonaire chez des patients ayant à la fois la BPCO et une fibrose pulmonaire, et chez des patients atteints d'une fibrose pulmonaire idiopathique sans BPCO, par stimulation de la synthèse de tensio-actifs pulmonaires et dans les sinus de patient humain et animal pour augmenter les fonctions pulmonaires, prévenir l'hypoxémie tout en réduisant les infections pulmonaires et des sinus, réduire certains effets secondaires du médicament, inhiber la fibrose et réduire la toux et l'érythème nasal. Les méthodes comprennent les étapes suivantes, consistant à : A) analyser et diagnostiquer un patient ayant un trouble pulmonaire choisi dans le groupe constitué par i) la BPCO et la fibrose pulmonaire ; et ii) la fibrose pulmonaire idiopathique sans BPCO ; et B) traiter le patient pour élever les fonctions pulmonaires du patient comprenant le rapport FEV1/FVC en mettant en contact des cellules de mammifère avec une quantité thérapeutiquement efficace d'une composition de traitement qui comprend une quantité thérapeutiquement efficace de chaque constituant de la composition.
Latest bibliographic data on file with the International Bureau